Relative Bioavailability Study of HR19042 in Healthy Subjects

Inclusion criteria

• Male or female subjects, ages 18 to 45, inclusive, at the time of informed consent.
• Female subjects weigh ≥ 45 kg, male subjects weigh ≥ 50 kg, and BMI between 19.0 and 28.0 kg/m2, inclusive, at screening.
• Understands the study procedures in the informed consent form ICF and be willing and able to comply with the protocol.

Exclusion criteria

• Subject with any history of severe allergic or anaphylactic reactions to any allergen including drugs, or allergic disease diagnosed and treated by a physician.
• Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders
• Subject has positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or treponema pallidum antibody.
• History of any gastrointestinal surgery or cholecystectomy that could impact the PK of study drugs.
• Participated in other clinical trials within 3 months before screening or plan to participate in other clinical trials during this study.
• Blood loss or blood donation of more than 300 mL within 3 months before screening, or intended to donate blood during the trial.
• Those who have been vaccinated with vaccines within 3 month before screening or who have an intention to vaccinate during the trial.
• Difficulty in venous blood sampling or fear of needles/blood.
• Difficulty in swallowing capsules, or inability to comply with the provided diet and study-related instructions.